Ranbaxy whistleblower on the perils of a globalized supply chain, fraud enablers
This article was originally published in Scrip
Countries that supply medicines to the US should be "incentivized" to upgrade their skills, comply with American quality standards and improve public health for their own citizens. And those that are repeatedly not up to scratch should face punitive action. So says Ranbaxy whistleblower Dinesh Thakur.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.